Structure-guided Discovery of Dual-recognition Chemibodies
暂无分享,去创建一个
A. Cheng | Zhulun Wang | Xiaoshan Min | P. Tagari | E. Doherty | Thomas E. Nixey | L. Miranda | E. Dimauro | A. Luthra | Jennifer H Dao | Jie Tang | S. Johnstone | Jay Ye
[1] P. S. Andersen,et al. Novel antibody–antibiotic conjugate eliminates intracellular S. aureus , 2015, Nature.
[2] C. Bertozzi,et al. Site-Specific Antibody–Drug Conjugates: The Nexus of Bioorthogonal Chemistry, Protein Engineering, and Drug Development , 2014, Bioconjugate chemistry.
[3] Andy Lin,et al. Structure-Based Druggability Assessment of the Mammalian Structural Proteome with Inclusion of Light Protein Flexibility , 2014, PLoS Comput. Biol..
[4] Chan Hyuk Kim,et al. Bispecific small molecule–antibody conjugate targeting prostate cancer , 2013, Proceedings of the National Academy of Sciences.
[5] E. Rosenthal,et al. A novel extracellular drug conjugate significantly inhibits head and neck squamous cell carcinoma. , 2013, Oral oncology.
[6] Philip R. Evans,et al. How good are my data and what is the resolution? , 2013, Acta crystallographica. Section D, Biological crystallography.
[7] Peter G. Schultz,et al. Reshaping Antibody Diversity , 2013, Cell.
[8] E. Perez,et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] N. Walker,et al. An Inhibitory Antibody against Dipeptidyl Peptidase IV Improves Glucose Tolerance in Vivo , 2012, The Journal of Biological Chemistry.
[10] Owen Johnson,et al. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM , 2011, Acta crystallographica. Section D, Biological crystallography.
[11] D. Drucker,et al. Incretin-based therapies for type 2 diabetes mellitus , 2009, Nature Reviews Endocrinology.
[12] E. Knapp,et al. Statistical thermodynamics of the stability of multivalent ligand-receptor complexes. , 2008, Physical review letters.
[13] M. Tadayyon,et al. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors , 2008, Journal of Pharmacology and Experimental Therapeutics.
[14] Randy J. Read,et al. Phaser crystallographic software , 2007, Journal of applied crystallography.
[15] Joanna Owens,et al. Target validation: Determining druggability , 2007, Nature Reviews Drug Discovery.
[16] G. Scapin,et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. , 2005, Journal of medicinal chemistry.
[17] Kevin Cowtan,et al. research papers Acta Crystallographica Section D Biological , 2005 .
[18] N. Thornberry,et al. Substituted piperazines as novel dipeptidyl peptidase IV inhibitors. , 2004, Bioorganic & medicinal chemistry letters.
[19] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[20] Collaborative Computational,et al. The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.
[21] A. C. Crawford,et al. SOME CONVENIENT LABORATORY APPARATUS , 1909 .
[22] Daniel R. Caffrey,et al. Structure-based maximal affinity model predicts small-molecule druggability , 2007, Nature Biotechnology.